IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study

IceCure says West Cancer Center IRB has granted clearance to start its ChoICE post-marketing study for ProSense breast cancer cryoablation.

Enrollment is expected to begin in the coming weeks.

ProSense holds FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy in women aged 70+.